Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Afatinib dose adjustment: Effect on safety, efficacy and patient-reported outcomes in the LUX-Lung 3/6 trials in EGFRm+ NSCLC
Vera Hirsh, Eng-Huat Tan, Yi-Long Wu, Lecia V. Sequist, Caicun Zhou, Martin Schuler, Sarayut L. Geater, Tony Mok, Cheng-Ping Hu, Nobuyuki Yamamoto, Jifeng Feng, Kenneth O’Byrne, Shun Lu, Yunchao Huang, Martin Sebastian, Isamu Okamoto, Nicolas Dickgreber, Riyaz Shah, Michael Palmer, Angela Märten, Dan Massey, Carl Samuelsen, James Chih-Hsin Yang
Learn more about the science behind this poster in the videos, papers and other materials below.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue